Kalkine has a fully transformed New Avatar.
The Offer
Company Overview
Hempacco Company Inc. is committed to disrupting the tobacco industry by creating and marketing tobacco- and nicotine-free alternatives to regular cigarettes. The business produces hemp- and herb-based smokable substitutes using a proprietary, patented spraying process for terpene infusion and a patent-pending flavored filter infusion technology. The business manufactures and sells smokable hemp and herb products, such as The Real Stuff Hemp Smokables, and has undertaken research and development in the smokables industry. Private label production and sales, intellectual property licensing, and the creation and marketing of in-house brands employing proprietary counter displays are some of the company's main sectors.
Key Highlights
Primary Offering: The Company is accepting applications for 1,000,000 Shares (1,150,000 if the underwriter exercises the over-allotment option in full) at a price of USD 6.00 per share to raise USD 6,000,000 (or 6,900,000 if underwriter exercises) before costs. The firm has given the underwriters a 45-day option to buy from it up to an extra 15% of the shares sold in the offering (or an additional 150,000 shares) at the price of the first public offering, less the underwriting discounts and fees.
Use of proceeds:
Dividend policy: On its common shares, the corporation has never declared or distributed any cash dividends. Hempacco does not foresee paying any cash dividends on its common shares anytime soon. Instead, it now expects to keep all cash on hand and any future revenues for use in running its company. In the future, the corporation may also sign credit agreements or other borrowing contracts that would limit its capacity to declare or pay cash dividends on the common shares. Any decision to pay dividends in the future will be at the board of directors' discretion and will be based on the company's financial situation, operating performance, capital needs, legal constraints, general economic circumstances, and any other relevant criteria that they may deem important.
Industry & Market Overview:
Financial Highlights (Expressed in USD):
Key Management Highlights
Risk Associated (High)
Investment in the IPO of “HPCO” is exposed to a variety of risks such as:
Conclusion
HPCO performance over the past three years shows strength of its business model and growing demand of its product offerings. Revenues, gross profit, and net losses all improved during the three months ended June 30, 2022, and the company reported healthy performance in the first half of FY22. It is anticipated that HPCO will have opportunities to grow using IPO funds and gain market share. Additionally, the company's recent spike in product demand bodes well for a long-term optimistic view. However, company is exposed to a large variety of risks ranging from regulatory headwinds to intense competition and supply chain issues due to geopolitical conditions.
Hence, given the financial performance of the company in the three-months ending June 30, 2022, narrowing losses, and associated risks “Hempacco Co., Inc.'s (HPCO)” IPO seems "Attractive for High-Risk Appetite Investors" at the IPO price.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.